A large, multi-institution study led by a Brown University physician-scientist could have important implications for the development of new classes of cancer therapeutics.

A study by the Mildred Scheel Early Career Center group led by Dr. Mohamed Elgendy at the TUD Faculty of Medicine provides fundamental insights into cancer biology.

This review synthesizes preclinical evidence showing that cinnamon-derived compounds can modulate inflammation, oxidative ...

Cancer drug resistance is the devastating reason that treatments fail and cancers metastasize, spreading to distant sites ...

In vitro studies pinpoint signaling pathways that could be potential targets in oral squamous cell carcinoma treatments.

Diabetes drugs may be doing more than managing blood sugar, they could also shape cancer biology in unexpected ways.

The biotech will now take atebimetinib to mid- and late-stage trials in NSCLC and pancreatic cancer, respectively.

Cirtuvivint is a selective pan-CLK, pan-DYRK inhibitor that modulates alternative RNA splicing, including transcripts involved in oncogenic pathways. Preclinical studies have shown that CLK/DYRK ...

The blood-based test by Astrin Biosciences shows high sensitivity and specificity across cancer stages and subtypes, ...

Interrupting one function of a protein that plays a key role in cell signaling could enable the development of new cancer treatments, according to a study led by Dr. Martin Taylor at the Warren Alpert ...